ATE502651T1 - Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors - Google Patents

Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors

Info

Publication number
ATE502651T1
ATE502651T1 AT95937946T AT95937946T ATE502651T1 AT E502651 T1 ATE502651 T1 AT E502651T1 AT 95937946 T AT95937946 T AT 95937946T AT 95937946 T AT95937946 T AT 95937946T AT E502651 T1 ATE502651 T1 AT E502651T1
Authority
AT
Austria
Prior art keywords
integrin receptor
pct
peptide
dna
date
Prior art date
Application number
AT95937946T
Other languages
English (en)
Inventor
Stephen Lewis Hart
Richard Paul Harbottle
Original Assignee
Ich Productions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9423231A external-priority patent/GB9423231D0/en
Priority claimed from GB9423308A external-priority patent/GB9423308D0/en
Priority claimed from GBGB9512822.9A external-priority patent/GB9512822D0/en
Application filed by Ich Productions Ltd filed Critical Ich Productions Ltd
Application granted granted Critical
Publication of ATE502651T1 publication Critical patent/ATE502651T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT95937946T 1994-11-17 1995-11-17 Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors ATE502651T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9423231A GB9423231D0 (en) 1994-11-17 1994-11-17 DNA compositions
GB9423308A GB9423308D0 (en) 1994-11-18 1994-11-18 DNA compositions
GBGB9512822.9A GB9512822D0 (en) 1995-06-23 1995-06-23 DNA Compositions
PCT/GB1995/002706 WO1996015811A1 (en) 1994-11-17 1995-11-17 Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand

Publications (1)

Publication Number Publication Date
ATE502651T1 true ATE502651T1 (de) 2011-04-15

Family

ID=27267477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937946T ATE502651T1 (de) 1994-11-17 1995-11-17 Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors

Country Status (8)

Country Link
US (1) US6083741A (de)
EP (1) EP0792166B1 (de)
JP (1) JPH10509166A (de)
AT (1) ATE502651T1 (de)
AU (1) AU3876695A (de)
CA (1) CA2204254C (de)
DE (1) DE69536153D1 (de)
WO (1) WO1996015811A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1997023608A1 (en) * 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
EP1129064B1 (de) 1998-11-12 2008-01-09 Invitrogen Corporation Transportreagentien
SE9900134D0 (sv) * 1999-01-15 1999-01-15 A & Science Invest Ab A method for introducing substances into cells, and use of said method
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
KR100784120B1 (ko) * 2000-06-02 2007-12-12 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 에틸렌디시스테인(ｅｃ)-약물 접합체
EP1322337A2 (de) * 2000-09-25 2003-07-02 Board of Regents, The University of Texas System Pei :dna vektor formulierungen zur in vitro und in vivo genverabreichung
JP2004533815A (ja) 2001-03-14 2004-11-11 ミリアド・ジェネティックス・インコーポレイテッド Ｔｓｇ１０１−ｇａｇ相互作用およびその使用
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
WO2003078576A2 (en) * 2002-03-12 2003-09-25 Nitto Denko Corporation Vector for transfection of eukaryotic cells
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
CA2505537A1 (en) * 2002-11-07 2004-05-27 Board Of Regents, The University Of Texas System Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2004062602A2 (en) * 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
WO2006137836A2 (en) * 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
JP5078987B2 (ja) * 2006-03-31 2012-11-21 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 遺伝子導入活性を有する新規なインテグリン結合ｒｇｄリポペプチド
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
GB0610636D0 (en) 2006-05-30 2006-07-05 Univ London Materials and complexes for the delivery of biologically-active material to cells
US20100159450A1 (en) 2006-06-23 2010-06-24 Susanne Wagner Dpyd gene variants and use thereof
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
AU2008218939B2 (en) * 2007-02-23 2014-05-08 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
KR101617790B1 (ko) * 2008-02-26 2016-05-03 아파르나 바이오사이언시스 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
EP2627351B1 (de) 2010-10-11 2018-12-26 GlaxoSmithKline Biologicals SA Antigenfreisetzungsplattformen
EP2667892B1 (de) 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Rsv-immunisierungstherapie
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP2729168A2 (de) 2011-07-06 2014-05-14 Novartis AG Immunogene zusammensetzungen und ihre verwendungen
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
WO2013054199A2 (en) 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
WO2014108515A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
EP3031822A1 (de) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus-Antigene
EP3047856A1 (de) 2015-01-23 2016-07-27 Novartis AG Cmv-antigene und ihre verwendungen
EP3341027B1 (de) 2015-08-28 2024-03-06 Molecular Transfer, Inc. Transfektionskomplexe und verfahren zur verwendung davon
WO2017151733A1 (en) 2016-03-01 2017-09-08 Molecular Transfer, Inc. Plant virus movement proteins and methods of using the same
GB201604235D0 (en) 2016-03-11 2016-04-27 Ucl Business Plc Lipids and complexes for the delivery of biologically-active material to cells
TW201936201A (zh) 2017-12-14 2019-09-16 美商堅固生物科技公司 基因之非病毒生產及遞送
EP4004018A1 (de) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modifizierte humane cytomegalovirus-proteine
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS586971B2 (ja) * 1979-12-26 1983-02-07 株式会社日立製作所 演算処理装置
JPH01255036A (ja) * 1988-04-04 1989-10-11 Toshiba Corp マイクロプロセッサ
JPH04221397A (ja) * 1990-12-20 1992-08-11 Fuji Photo Film Co Ltd 水溶性ポリペプチド誘導体とその用途
AU677208B2 (en) * 1992-05-21 1997-04-17 Cis Bio International Technetium-99m labeled peptides for thrombus imaging
AU6254494A (en) * 1993-02-16 1994-09-14 Virginia Tech Intellectual Properties, Inc. Polyelectrolyte dna conjugation and genetic transformation of an animal
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides

Also Published As

Publication number Publication date
DE69536153D1 (de) 2011-05-05
US6083741A (en) 2000-07-04
CA2204254C (en) 2010-02-16
WO1996015811A1 (en) 1996-05-30
CA2204254A1 (en) 1996-05-30
EP0792166B1 (de) 2011-03-23
AU3876695A (en) 1996-06-17
JPH10509166A (ja) 1998-09-08
EP0792166A1 (de) 1997-09-03

Similar Documents

Publication Publication Date Title
ATE502651T1 (de) Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
DE59410071D1 (de) Adenovirus für den transport von fremd-dna in höhere eukariotische zellen
EP1392835A4 (de) Epressionsvektor für tierische zellen
Leppla et al. Anthrax toxin fusion proteins for intracellular delivery of macromolecules
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
AR001731A1 (es) Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DK2351844T3 (da) Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
ATE330007T1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
ATE325533T1 (de) Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
NZ514488A (en) Vascular endothelial cell growth factor variants and uses thereof
RS50831B (sr) Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid
ATE246935T1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
ATE449173T1 (de) 32144, eine humane fettsäureamid-hydrolase und deren verwendungen
WO1998016255A3 (en) Stabilized conjugates of uncomplexed subunits of multimeric proteins
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
DE50011068D1 (de) Fragmente des virus proteins 2 oder 3 des polyomavirus als fähren für wirkstoffe
NO962927L (no) Hestearteritt-virus peptider, antistoffer og deres anvendelse i en diagnostisk test
DE69738526D1 (de) Extrazelluläre expression von zellulose bindenden domänen (cbd) unter verwendung von bacillus
FI962047A0 (fi) Endoteliiniä muuntava entsyymi
ATE353103T1 (de) Humaner kappa opiatrezeptor, nukleinsäuren und ihre verwendungen
WO2002010391A3 (en) 18610, a human transient receptor and uses thereof
NO20020604L (no) Fremgangsmåte for avlevering av terapeutiske midler ved bruk av en dekstrinlösning

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties